Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076088 | 0.72 | NR4A2 (0.35) | NR4A2SMN1; SMN2KDM4EPOLBRAB9A | |
| SCHEMBL24149773 | 0.71 | TGFBR1 (0.39) | NR4A2SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL24149951 | 0.71 | RAB9A (0.38) | NR4A2SMN1; SMN2KDM4EMEN1POLB | |
| SCHEMBL5036842 | 0.70 | ALDH1A1 (0.56) | SMN1; SMN2KDM4EMEN1POLBKMT2A | |
| SCHEMBL4159114 | 0.70 | NR4A2 (0.33) | NR4A2SMN1; SMN2KDM4ERAB9ACCNC | |
| SCHEMBL2075029 | 0.68 | JAK2 (0.42) | NR4A2SMN1; SMN2KDM4EPOLBKMT2A | |
| SCHEMBL4167350 | 0.68 | NR4A2 (0.32) | NR4A2 | |
| SCHEMBL4800668 | 0.68 | HPGD (0.34) | NR4A2SMN1; SMN2KDM4E | |
| SCHEMBL4161630 | 0.66 | NR4A2 (0.31) | NR4A2SMN1; SMN2KDM4E | |
| SCHEMBL3952505 | 0.66 | JAK2 (0.47) | NR4A2SMN1; SMN2KDM4EKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751146-B1 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318954-A1 | Compounds | CBR3, NR3C2, NR5A1 | NR4A2 181/4885SMN1; SMN2 1388/4885KDM4E 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.